The pharmacotherapy management of patients with heart failure with reduced ejection fraction is a populated landscape with multiple drugs affecting morbidity and mortality. Two new medications that are the first in two new classes were approved recently - a neprilysin inhibitor and a hyperpolarization-activated cyclic nucleotide-gated channel blocker.
But first here's a quick table and a few notes about the current use of medications for treating heart failure with reduced ejection fraction.
HughesMedicine - Pharmacotherapy Pearls from the Internal Medicine Clinical Pharmacist
Recommended for you
-
The 2016 American Diabetes Association diabetes guidelines is a lengthy document outlining many aspects of diabetes care including eval...
-
Let’s start with a patient case. A patient is being treated with methylprednisolone 20 mg IV q6 hours for some inflammatory process and...
-
A 48 year old male is admitted to the hospital after experiencing a fever and malaise for several days. He states that he has some shortn...
-
A 55 year old business executive is being discharged from the hospital after a brief admission for cellulitis. His only PMH is HTN and o...
-
Daptomycin (Cubicin) is the first antibiotic in a class known as lipopeptides and has a unique mechanism of action. Daptomycin is a large...
-
Since July is here and the academic calendar is starting over, it is time for new medical residents to be arriving to the hospital floors...
-
Homeopathy is a part of complementary and alternative medicine (CAM) that is an undeniable component of the healthcare industry in the U...
-
The American Geriatrics Society recently published their Alternative Treatments to Selected Medications in reference to the most recent upd...
-
A 60 year old female patient presents to the emergency department with complaints of swelling and pain in her right leg. She recently had...
-
Midodrine is a peripherally-acting selective alpha1 receptor agonist . Let's take that sentence apart to see what we should expect ...
